HYAL1 and neoplasm: Our study suggests that neutral pH-active HYAL1, facilitated by acidic residue substitutions, presents a versatile alternative for PH20 for various clinical applications, including subcutaneous delivery of therapeutic antibodies, tumor HA degradation for cancer therapy, enhancement of local anesthetic spread and absorption during ophthalmological surgery, and treatment for HA filler complications [45–48].